NDA 020517 · Abbvie Endocrine INC
Lupron Depot
Leuprolide Acetate · Injection
Last checked: Nov 20, 2026Latest source record: Aug 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1995
Dec 22, 1995
Approved uses
4
Original approval plus efficacy supplements
Registered trials
457
123 Phase 3, 53 recruiting
FAERS reports
29,123
17,188 serious, 4,144 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 15, 2026.
LUPRON DEPOT 7.5 mg for 1-month administration, 22.5 mg for 3-month administration, 30 mg for 4-month administration, and 45 mg for 6-month administration (leuprolide acetate) are indicated for the treatment of advanced prostate cancer. LUPRON DEPOT is a gonadotropin releasing hormone (GnRH) agonist indicated for: treatment of advanced prostate cancer. ( 1 )
Mechanism: Leuprolide acetate, a GnRH agonist, acts as an inhibitor of gonadotropin secretion. Animal studies indicate that following an initial stimulation, continuous administration of leuprolide acetate results in suppression of ovarian and testicular steroidogenesis. This effect was reversible upon discontinuation of drug therapy. Administration of leuprolide acetate has resulted in inhibition of the growth of certain hormone dependent tumors (prostatic tumors in Noble and Dunning male rats and DMBA-induced mammary tumors in female rats) as well as atrophy of the reproductive organs.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 18, 2022 Supplement 43 · Efficacy LetterLabel
- Jun 17, 2011 Supplement 30 · Efficacy ReviewLetterLabel
- May 30, 1997 Supplement 2 · Efficacy Review
- Dec 22, 1995 Original approval · Type 3 - New Dosage Form ReviewOther Important Information from FDA
3 products under this application
- LUPRON DEPOT · LEUPROLIDE ACETATE 45MG · INJECTABLE, INJECTION · Prescription
- LUPRON DEPOT · LEUPROLIDE ACETATE 22.5MG · INJECTABLE, INJECTION · Prescription
- LUPRON DEPOT · LEUPROLIDE ACETATE 30MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Leuprolide" as an intervention, any sponsor and status, largest first.
- Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast CancerPivotal-lookingCompleted
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00002582 · 6,000 participants (planned) · Start Jun 1993
Drug: CMF regimen; cyclophosphamide and 6 more · For: Breast Cancer
Sites: Birmingham, United Kingdom; Glasgow, United Kingdom
- RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local SurgeryPivotal-lookingCompleted
University College, LondonAcademic, hospital or other
NCT00541047 · 4,236 participants · Start Nov 2007 · Primary completion Jul 27, 2022
Drug: bicalutamide; goserelin acetate and 1 more · For: Gastrointestinal Complications; Prostate Cancer; Sexual Dysfunction and 1 more
Sites: Kelowna, Canada; Vancouver, Canada; London, Canada · 58 sites in all
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04961996 · 4,170 participants · Start Aug 27, 2021 · Primary completion Aug 8, 2025
Drug: Giredestrant; Physician's Choice of Endocrine Therapy and 1 more · For: Early Breast Cancer
Sites: Daphne, Alabama; Bakersfield, California; Fullerton, California · 621 sites in all
NRG OncologyAcademic, hospital or other
NCT05879926 · 3,960 participants (planned) · Start Oct 18, 2023 · Primary completion Jan 2032
Drug: Ovarian Function Suppression + Aromatase Inhibitor; Adjuvant Chemotherapy + Ovarian Function Suppression · For: Breast Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 1,276 sites in all
- Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02941926 · 3,246 participants · Start Nov 30, 2016 · Primary completion Nov 8, 2019
Drug: Ribociclib; Letrozole and 2 more · For: Breast Cancer
Sites: Anchorage, Alaska; Chandler, Arizona; Phoenix, Arizona · 495 sites in all
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialPivotal-lookingActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT04513717 · 2,753 participants · Start Jan 21, 2021 · Primary completion Dec 31, 2033
Drug: Apalutamide; Bicalutamide and 8 more · For: Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
Sites: Fairbanks, Alaska; Gilbert, Arizona; Peoria, Arizona · 602 sites in all
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialPivotal-lookingActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT05050084 · 2,050 participants (planned) · Start Dec 6, 2021 · Primary completion Nov 11, 2026
Drug: Bicalutamide; Buserelin and 8 more · For: Prostate Adenocarcinoma
Sites: Birmingham, Alabama; Gilbert, Arizona; Peoria, Arizona · 576 sites in all
- Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate CancerPivotal-lookingCompleted
Radiation Therapy Oncology GroupResearch network
NCT00002597 · 2,028 participants · Start Oct 1994 · Primary completion Jul 2011
Drug: flutamide; Zoladex and 1 more · For: Prostate Cancer
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 239 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hot flush3,487
- death2,333
- fatigue1,923
- headache1,462
- pain1,285
- drug ineffective1,187
- nausea1,180
- arthralgia1,082
- asthenia998
- abdominal pain942
- off label use938
- vaginal haemorrhage878
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 127 |
| 2005 | 119 |
| 2006 | 106 |
| 2007 | 141 |
| 2008 | 506 |
| 2009 | 978 |
| 2010 | 1,324 |
| 2011 | 1,582 |
| 2012 | 1,181 |
| 2013 | 1,670 |
| 2014 | 2,641 |
| 2015 | 2,663 |
| 2016 | 1,865 |
| 2017 | 1,342 |
| 2018 | 1,384 |
| 2019 | 1,495 |
| 2020 | 1,350 |
| 2021 | 1,527 |
| 2022 | 1,854 |
| 2023 | 1,614 |
| 2024 | 1,500 |
| 2025 | 1,148 |
| 2026 | 1,006 |
Recalls
3 FDA enforcement reports for this application.
Mar 10, 2014 · Class II · Terminated
Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device.
Mar 10, 2014 · Class II · Terminated
Defective Delivery System: Some Lupron Depot Kits may containin a syringe with a potentially defective LuproLoc needle stick protection device.
Mar 10, 2014 · Class II · Terminated
Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lupron Depot (Leuprolide Acetate)
2024 spending
$164M
Beneficiaries
11,482
31,645 claims
Per beneficiary
$14,283
$5,177.85 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $82,608,206 |
| 2021 | $82,903,168 |
| 2022 | $107,502,481 |
| 2023 | $128,884,249 |
| 2024 | $163,997,487 |
Part B: Lupron Depot* (Leuprolide Acetate*) · HCPCS J1950
2024 spending
$11.2M
Beneficiaries
1,111
4,163 claims
Per beneficiary
$10,111
2024 ASP limit $1,608.08 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,502,353 |
| 2021 | $6,456,999 |
| 2022 | $8,232,155 |
| 2023 | $10,345,855 |
| 2024 | $11,233,617 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Freedland SJ, de Almeida Luz M, De Giorgi U, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Comparative Study
- Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Shore ND, Saad F, Cookson MS, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Comparative Study
- Pharmacologic Interventions for Endometriosis-Related Pain: A Systematic Review and Meta-analysis.
Kou L, Huang C, Xiao D, et al. · Obstet Gynecol 2025 · Systematic Review, Network Meta-Analysis
- Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Shore ND, Luz MA, De Giorgi U, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Cluster headache.
Matharu M, Silver N · BMJ Clin Evid 2008 · Systematic Review
- The Effect of Hormonal Treatment on Ovarian Endometriomas: A Systematic Review and Meta-Analysis.
Thiel PS, Donders F, Kobylianskii A, et al. · J Minim Invasive Gynecol 2024 · Meta-Analysis, Systematic Review
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.